Ikena Oncology
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
645 Summer St Ste 101, Boston, Massachus...Phone Number
(857) 273-8343Website
www.ikenaoncology.comRevenue
<$5 MillionStock Symbol
IKNAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Ikena Oncology
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Explore more
Ikena Oncology Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ikena Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Ikena Oncology launches new products
Click to see if Ikena Oncology had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Ikena Oncology has new funding data
Check if Ikena Oncology has recently received funding, and reach out quickly before it becomes old news!
Ikena Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Ikena Oncology recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Ikena Oncology
Check out if Ikena Oncology is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Ikena Oncology
Find more new buyers
Compare Similar Companies to Ikena Oncology
Compare insights from companies similar to Ikena Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ikena Oncology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ikena Oncology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ikena Oncology.
Ikena Oncology financials insights
Gather financial insights about Ikena Oncology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$49M
2021
Series B
$120M
Ikena Oncology Tech Stack
A closer look at the technologies used by Ikena Oncology
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Ikena Oncology News & Media
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio (“Imagene”), of the combined company after the anticipated closing.Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”) recommend that stockholders vote FOR the issuance of shares in connection with the previously disclosed proposed merger with Inmagene Biopharmaceuticals (“Inmagene”) at Ikena’s upcoming Annual Meeting of Stockholders on July 15, 2025.Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC functionIkena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Ikena Oncology
Sign Up For FreeTo access detailed company insights
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also dev... Read More
